Phenytoin is associated with an increased risk of congenital malformations, particularly neural tube defects and facial anomalies, when taken during pregnancy. Women of child-bearing potential should use effective contraception and discuss potential alternatives with their physician.
Dizziness, ataxia, or visual disturbances can occur, especially during dose titration. Patients should assess their own steadiness and avoid driving or operating machinery until they are confident the medication does not impair their abilities.
Steady-state concentrations typically develop after 5-7 days of consistent dosing, though the exact time may vary with age, liver function, and concurrent medications.
Any skin eruption, especially if it spreads or blisters, warrants immediate medical evaluation. Severe reactions like Stevens-Johnson syndrome require urgent discontinuation of the drug and emergency care.
Gingival hyperplasia is a known side effect of chronic phenytoin therapy. Good oral hygiene, regular dental check-ups, and possibly dose reduction can help manage this condition.
Yes. Phenytoin induces enzymes that can lower hormone levels, decreasing contraceptive effectiveness. Additional non-hormonal contraception or a switch to a less interactive antiepileptic may be advisable.
Phenytoin absorption is relatively consistent regardless of meals. Some patients find taking the tablet with a light snack reduces gastrointestinal upset, but this is not a requirement.
Symptoms include pronounced nystagmus, slurred speech, unsteady gait, confusion, and in severe cases, respiratory depression or coma. Laboratory confirmation via elevated serum levels supports the clinical picture.
Keep the tablets in their original container, at room temperature, and protect them from excess heat, humidity, or direct sunlight. Carry a copy of the prescription and a letter from your doctor if you need to cross customs with a controlled medication.
Factors such as enzyme induction by other drugs, rapid metabolism, missed doses, or malabsorption can lower serum concentrations. Regular monitoring and dose adjustments guided by a clinician can resolve the issue.
Dilantin is a brand name for the medication phenytoin, an antiepileptic drug used primarily in the field of neurology. It is available in the United Kingdom as a 100 mg oral pill and is classified as a prescription-only medicine (POM) by the Medicines and Healthcare products Regulatory Agency (MHRA).
Phenytoin stabilises neuronal membranes by selectively blocking voltage-gated sodium channels. By prolonging the inactivated state of these channels, the drug reduces the rapid influx of sodium ions that underlies the high-frequency firing of epileptic neurons. This action diminishes the spread of abnormal electrical activity across the cerebral cortex, helping to prevent seizure recurrence.
Key pharmacologic points:
In the UK, phenytoin is approved for the following indications:
These approvals are based on clinical trial data and decades of clinical experience demonstrating efficacy in reducing seizure frequency for the listed seizure types.
Phenytoin has been explored for several off-label indications, most notably:
Disclaimer: Off-label use of Dilantin should only be undertaken under direct supervision of a qualified healthcare professional, with individualized monitoring for efficacy and safety.
Phenytoin is a potent inducer of several cytochrome P450 enzymes (CYP2C9, CYP2C19, CYP3A4). This property can reduce plasma concentrations of co-administered drugs, potentially compromising their efficacy. Notable interactions include:
This article provides educational information about Dilantin (phenytoin) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
